Extracellular Vesicle Isolation via Multimodal Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating extracellular vesicles (EVs) from biological fluids, such as ultracentrifugation, face challenges in achieving high purity and throughput due to contamination from lipoprotein particles and free plasma proteins, which complicates downstream analysis and is not scalable for large sample processing.
Innovation Solution
The use of multimodal chromatography-based methods, specifically employing multimodal chromatography resins like CaptoCore 400 and CaptoCore 700, in combination with size exclusion chromatography, to effectively deplete plasma proteins and lipoprotein particles, allowing for the isolation and purification of EVs with higher purity and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If ultracentrifugation is used to isolate EVs, then EVs can be separated from other biomolecular species, but the process is time-consuming and low throughput
Solution Approach 1:
The patent replaces the mechanical ultracentrifugation system with a chromatography-based separation system. The chromatography method uses stationary phases with specific pore sizes and chemical properties to separate EVs from plasma components through diffusion and adsorption mechanisms, eliminating the need for high-speed centrifugation while achieving comparable or superior purity and dramatically increasing throughput.
Solution Approach 2:
The patent changes the separation parameters by using chromatography conditions (mobile phase composition, flow rate, stationary phase properties) instead of centrifugation parameters (speed, time, density gradients). This allows for high-throughput processing while maintaining separation efficiency through optimized chromatographic parameters such as pore size selection and buffer composition.
2Manufacturing precision
If ultracentrifugation is used to isolate EVs, then EVs can be separated from other biomolecular species, but the process is expensive and not easily scalable
Solution Approach 1:
The patent replaces the mechanical ultracentrifugation system with a chromatography-based separation system. The chromatography method uses stationary phases with specific pore sizes and chemical properties to separate EVs from plasma components through diffusion and adsorption mechanisms, eliminating the need for high-speed centrifugation while achieving comparable or superior purity and dramatically increasing throughput.
Solution Approach 2:
The patent segments the plasma sample into different molecular weight fractions using chromatography columns with specific pore sizes. This segmentation approach allows for parallel processing of multiple samples through different column configurations, enabling scalable high-throughput isolation without the complexity and cost of ultracentrifugation equipment.
3Manufacturing precision
If ultracentrifugation is used to isolate EVs, then EVs can be separated from other biomolecular species, but lipoprotein particles and free plasma proteins contaminate the sample
Solution Approach 1:
The patent employs porous chromatography resins with specifically engineered pore sizes (e.g., 100-200 nm) that allow free plasma proteins and small lipoprotein particles to enter and be retained, while EVs are excluded from the pores and elute in the void volume. This size-based exclusion mechanism achieves superior purity by physically preventing contamination from smaller molecular species.
Solution Approach 2:
The patent changes the separation parameters by using chromatography conditions (mobile phase composition, flow rate, stationary phase properties) instead of centrifugation parameters (speed, time, density gradients). This allows for high-throughput processing while maintaining separation efficiency through optimized chromatographic parameters such as pore size selection and buffer composition.
4Manufacturing precision
If washing with PBS is performed post-UC processing to obtain purer EV samples, then purity increases, but sample losses occur
Solution Approach 1:
The patent performs the separation action preliminarily by using chromatography to isolate EVs in a pure form directly from the beginning, eliminating the need for subsequent washing steps. The chromatography process inherently separates EVs from contaminants in a single step, achieving high purity without the sample loss associated with repeated washing and concentration cycles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in EV isolates with similar purity to traditional methods but offers advantages in simplicity, throughput, and scalability, enabling more effective downstream analysis and potential clinical applications by reducing contamination and sample processing time.
Implementation Method 1
size exclusion chromatography (SEC) have made it possible to exploit the differences in EVs and to separate them from other highly abundant molecular and macromolecular species
Implementation Method 2
contacting the sample with the multimodal chromatography resin for an incubation period
Data Source
AI summary
The present technology provides straightforward, reproducible, scalable, and efficient multimode chromatography-based methods for the effective isolation and/or purification of nanoparticulate biomaterials from mixtures of biomaterials. The methods can be used to isolate and purify extracellular vesicles and other nanoparticulate biomaterials from plasma and other sources to provide high purity products. The methods can be used to diagnose medical conditions and to prepare pharmaceutical products.